(NewsDirect)
Faron Pharmaceuticals Limited (AIM:FARN,OTC:FPHAF) chief executive Dr Markku Jalkanen speaks to Thomas Warnerfrom Proactive London after the clinical stage biopharmaceuticalcompany announced "very positive" Phase 1 data from theongoing BEXMAB study in myeloid malignancies.
The data is being presented at the 65thAmerican Society of Hematology (ASH) Annual Meeting & Expositiontaking place until tomorrow, December 12, 2023, in San Diego,California, and virtually. Jalkanen says the data reveals a promisingresponse in patients, especially in inducing myeloid differentiationin Myelodysplastic Syndrome (MDS), a condition with limited treatmentoptions
Typically, patients withthis type of cancer have a life expectancy of around 24 months, makingthese results particularly significant. Investors and shareholdershave responded positively to this latest news, as the trial shows aresponse rate potentially 5 to 10 times higher than the currentstandard of care. Faron Pharmaceuticals is now preparing to advance tothe next trial phases and is exploring potential partnerships.
Regarding the company's overallperformance in 2023, Dr. Jalkanen expresses satisfaction withFaron's ability to maintain and even increase its pace, withpromising data accumulating from ongoing trials and the initiation ofnew ones. The company is targeting a marketing approval application by2025, staying on track with its previously set goals.
Contact Details
Proactive UK Ltd
+44 207989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.